Clinical Trial Update: Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept trial of imatinib (Gleevec) in active diffuse systemic sclerosis (scleroderma) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Scleroderma | Phase 2 | Status: TERMINATED